Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

Share on StockTwits

Contakt World Technologies Partnership Will Help Satisfy Demand for Vaccine Passport Technology

Source: Streetwise Reports

November 15, 2021 ( Newswire) Contakt World plans to build a diversified health technology SaaS platform and address inequity of health access through technology.

Inequity in healthcare access came into sharp focus during the
pandemic, as did the need for contact tracing technology. Contakt World Technologies Corp. (HELP:CSE; TLOOF:OTC) was founded to deliver solutions that target marginalized communities and try to level the playing field, according to the company. Contakt World's latest move provides access to vaccine passport technology through a partnership with Portum announced October 14.

With COVID and the widespread Delta variant, symptom screening, vaccine passports, vaccine validation, vaccine wallets, vaccine credentials, and other methods to improve population safety and reduce liability to restoring everyday business, travel, and social life are needed more than ever by employers and institutions.

Portum's vaccine passports and wallets provide a secure proof of vaccination for monitoring guests' access to events or venues. Contakt World will offer the Portum platform to commercial and government customers to meet and monitor vaccine mandates in public and private settings, exposure notification, symptom checker, secure vaccine wallet, and distancing notifications.

The revenue-sharing partnership with Portum will leverage Portum's technology across Contakt World's private and public sector clients.

Contakt World was formed in 2020 as a contact tracing company with health equity in mind, explains interim CEO Zayn Kalyan. At first, people could access the decentralized early exposure notification App pioneered by Google and Apple called GAEN that would only run in the latest digital devices, excluding a wide swath of underserved communities. The company believes that "technology has the ability to address inequity with solutions that can be deployed and used by people in marginalized communities who do not have the latest devices," he says.

Smart Health RM, a relationship management software built from the ground-up with public health in mind, was Contakt's first SaaS software application. Initiated to aid public health agencies with tracking and containing the spread of COVID, Smart Health has a particular focus on contact tracing and community engagement communication channels leveraging AI technology (smart text surveys).

The long lead-time selling into the public sector led the company in the direction of private organizations that rely of technology to protect its workforce, targeting companies with as many as 10,000 employees with its newer health technologies. "Public health agencies have a very long sales cycle and we have realized our efforts should be on private enterprises, such as private real estate companies, private schools, event venues with a large on-site staff and daily visitors," Kalyan says.

Contakt World acquired its second platform, HealthCheck, in August, a symptom management tool that helps HR departments and healthcare professionals monitor the well-being of those who report to work or school each day. Organizations can screen, approve, and protect visitors, as well as customers, employees, or students using the Health Check platform. Over 100,000 people across 1,000 client organizations currently use the platform.

HealthCheck's positive cash flow, existing client base, and the market demand for symptom management made the company an attractive target to "not only grow the HealthCheck business but to expand its offering to further meet the needs of its existing and new customers," explains Kalyan.

"We anticipate launching a new version of the HealthCheck app in December of this year, adding the vaccine passport and testing tracking features. We have been experiencing a significant demand for these features as business race to meet the federal vaccine mandate from the U.S. government for employers with 100 or more employees."

The one-year-old company went public in July 2021. VC firm Altus Capital is one of the founding investors and Kalyan is an Altus partner serving as CEO on an interim basis. He said the company is currently planning the Portum rollout to Contakt World customers.

"When we acquired HealthCheck we were concerned about how sustainable the business might be. I was pleasantly surprised in the growth," recognizing it is now clear that COVID will have a lasting effect on the health technology needs surfaced during the pandemic. "We want to build a more diversified health care platform," he says.

Contakt World is looking at a number of strategic acquisitions in the coming months, setting its sights on a durable model that extends well beyond COVID. "The goal is to build a diversified group of healthcare and health tech businesses and use the platform to cross-sell the different offerings." Areas of interest beyond COVID include long-term care, chronic care delivery, digital pharmacy, and telehealth, he said. He said the company intends to build it into a comprehensive health tech platform.

"We have existing clients and wanted to be able to offer a greater suite of services to them," Kalyan states. Portum is known for delivering vaccine passports for events, such as concerts, sports competitions, and other events. Vaccine passports for events is their core. Contakt World wants to deliver Portum technology to its existing customers, who are looking for digital resources that keep their visitors and employees safe.

Symptom screening, vaccine passports, vaccine validation, vaccine wallets, vaccine credentials and other methods are employed to improve population safety and reduce liability. In light of COVID-19 and its Delta variant, the technology is becoming key to everyday business, travel, and social life.

In the Portum partnership, "we own the customer; they deliver the solution via a SaaS subscription model," which Kalyan calls affordable. For example, a private school with 200-300 people may pay $4,000-$5,000 a year.

The pace is quickening for vaccine passport technology. Many large employers and state agencies may build their own, and there are other players in the space, such as Clear, the travel services company. "It's a massive marketplace and that's where we see the opportunity to build on our own client base and scale out from there," Kaylan concludes.


1) Gerri Leder compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor/employee. He/she or members of his/her household own securities of the following companies mentioned in the article: None. He/she or members of his/her household are paid by the following companies mentioned in this article: None. His/her company has a financial relationship with the following companies referred to in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Contakt World Technologies Corp. Please click here for more information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

4) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Contakt World Technologies Corp., a company mentioned in this article.

5) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Follow Us on StockTwits - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on